Delivery Order SPE2DB22D3004-SPE2DB26FQ86E
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,989.35 to AmerisourceBergen Drug Corp for Copaxone 40 mg/ml syringes, with completion scheduled for July 22, 2025. This non-set-aside, competitively awarded contract reflects a firm fixed price arrangement typical of pharmaceutical procurement through the federal medical supply chain. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for...
- The Defense Logistics Agency awarded a $1,638.00 delivery order to AmerisourceBergen Drug Corp for Copaxone 40 mg/ml syringes, with a completion date of September 10, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Copaxone 20 mg/ml syringes, valued at $4,467.22, with an ultimate completion date of July 28, 2025. This non-competitive delivery order employs firm fixed-price terms and represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to federal medical procurement needs. The work will be performed at the company's corporate office location in Conshohocken,...
- AmerisourceBergen Drug Corp was awarded a delivery order for Copaxone 40 mg/ml syringes valued at $1,041.36 by the Defense Logistics Agency's Medical Supply Chain on August 19, 2025. This competitive, firm fixed-price contract has an ultimate completion date of August 20, 2025, and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, which is valued at $999,999,999 and extends through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a $15,154.14 delivery order to AmerisourceBergen Drug Corp for the supply of Copaxone 20 mg/ml syringes. The contract, which was competitively awarded without set-aside designation, became effective on April 21, 2025, with an ultimate completion date of April 22, 2025. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a firm fixed-price delivery order, this award represents a discrete fulfillment...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $2,218.86 to supply Copaxone 40 mg/mL syringes. This competitively awarded, firm fixed-price contract, issued on October 15, 2025, with an ultimate completion date of October 16, 2025, represents a direct fulfillment of pharmaceutical needs through the company's existing indefinite delivery vehicle. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $1,092.00 firm fixed price delivery order to AmerisourceBergen Drug Corp for Copaxone 40 mg/ml syringes, with a completion date of September 11, 2025. This non-set-aside competitive award represents a single delivery order issued under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 7, 2025, for the supply of Copaxone 40 mg/mL syringes with a ceiling value of $2,146.06 and an ultimate completion date of November 10, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The contract specifies performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's corporate headquarters and a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,522.65 to AmerisourceBergen Drug Corp for the supply of Copaxone 20 mg/mL syringes. The contract is a firm fixed-price delivery order with no set-aside designation, indicating competitive award to the vendor. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of October 22, 2025. This delivery order is a child contract issued under...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency for Copaxone 40 mg/ml syringes valued at $1,712.99. The award was made on October 29, 2025, with an ultimate completion date of October 30, 2025, under a Firm Fixed Price contract type with no set-aside designation. This delivery order represents a competitive procurement action and falls under the company's broader Indefinite...
- SPE2DB22D3004Indefinite Delivery Contract
- SPE2DB22D3004-SPE2DB26FQ86EDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,160.60 for Copaxone 20 mg/ml syringes, with an ultimate completion date of November 5, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside procurement issued to the prime contractor's corporate office in Conshohocken, Pennsylvania. The award is executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive $999,999,999.00 global pharmaceutical support vehicle running through December 2026 that enables the company to supply pharmaceutical products and medical supplies to military healthcare programs worldwide. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting the Defense Health Agency and other government healthcare systems. The company's extensive portfolio of federal contract awards demonstrates its capability to fulfill diverse medical supply requirements across multiple therapeutic domains, including specialty medications, vaccines, and medical devices. This delivery order for Copaxone, a disease-modifying therapy for multiple sclerosis, reflects the company's ongoing role in supplying specialized pharmaceutical products to support military and veteran healthcare needs through the DLA's medical supply chain operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 11/4/25 |